Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ligand Pharmaceuticals
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fasting plasma glucose between 120 - 270 mg/dL at screening
HbA1c measurements between 6.0 - 10% at screening
Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal ligation). Females who are postmenopausal for at least 12 consecutive months and documented by blood follicular stimulating hormone (FSH) greater than or equal to 40 mlU/mL.Females of childbearing potential must be willing to use an approved double-barrier method of birth control (e.g. condom plus spermicide ;IUD plus spermicide) from the time of signing the informed consent form through 4 weeks following the last dose of study drug.
Body mass index (BMI) in the range of 18.5 - 37 kg/m2 Patients with a BMI in the range of 37.5 - 40 kg/m2 who in the Investigator's opinion, are in good health and satisfy the eligibility criteria, will be considered on a case-by case basis
Written informed consent
You may not be if
Type 1 diabetes mellitus
Type 2 diabetes mellitus with a history of diabetic ketoacidosis or ketosis-prone
Use of thiazolidinediones (TZDs)
Currently on more than two oral hypoglycemic agent
History of outpatient insulin use
Clinically significant history of cardiac disease within 6 months of informed consent
Clareo Health | Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
